The Detection of sAMY1α in Ovarian Cancer Ascites During First-Line Chemotherapy Predict the Response of Patients to Treatment

Background: Ovarian cancer ascites are a clinical conundrum in the process of diagnosis and treatment, and chemotherapy is the main treatment. The efficacy and prognostic assessment of chemotherapy has been the subject of continuous exploration. Methods: Affymetrix HTA2.0 microarray analysis of ovarian cancer ascites without and with chemotherapy, as well as metabolomics techniques, showed that AMY1A gene expression in the chemotherapy was significantly higher than that without chemotherapy.Results: The analysis of ovarian cancer tissues, ascitic precipitated cells and supernatants, showed that the high expression of sAMY-1α was negatively correlated with HE4 (p<0.01), and was also negatively correlated with the expression of the Beclin1 and LC3 (p<0.05, p<0.001) in group with chemotherapy. The results of ovarian cancer cell lines OVCAR3 and A2780, which were treated with autophagic inhibitor (3MA), inducer (rapamycin) or cisplatin (CDDP), were consistent with it. The results of 3MA group showed that as the drug concentration increased, there were decreased in the levels of Beclin1 and LC3II, and sAMY1α levels increased. There was opposite result in rapamycin group. CDDP group revealed significantly decreased levels of LC3II, Beclin1, and increased levels of sAMY1α; when rapamycin was added, autophagy inhibition was alleviated, and slightly reduced levels of sAMY1α. The results indicated that chemotherapy induced autophagic death of tumor cells, and the expression of sAMY1α in ascites of chemotherapy reflected the degree of autophagic death of tumor cells. Conclusions: During the diagnosis and treatment of ovarian cancer ascites, the expression level of sAMY1α was detected at any time, compared with the levels of HE4, Beclin1 and LC3 in the ascites with chemotherapy, and compared with the serum level of CA125 in the patients, so that the recurrence of ascites could be predicted. Therefore, the adjustment of treatment regimen has important guiding significance.